Format

Send to

Choose Destination
Nat Rev Nephrol. 2018 Jul;14(7):428-441. doi: 10.1038/s41581-018-0006-6.

Diagnosis and management of resistant hypertension: state of the art.

Author information

1
Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium.
2
Institut universitaire de médicine sociale et préventive, University of Lausanne, Lausanne, Switzerland.
3
Department of Cardiovascular Diseases, Shanghai General Hospital, Shanghai, China.
4
Center for Epidemiological Studies and Clinical Trials and Center for Vascular Evaluations, Shanghai Institute of Hypertension, Shanghai Key Laboratory of Hypertension, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
5
Studies Coordinating Centre, Research Unit Hypertension and Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Diseases, University of Leuven, Leuven, Belgium. jan.staessen@med.kuleuven.be.
6
Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, Netherlands. jan.staessen@med.kuleuven.be.

Abstract

Resistant hypertension is defined as a lack of ambulatory blood pressure response to optimized medical treatment after exclusion of secondary hypertension in patients who are fully adherent to antihypertensive therapy. Patients with resistant hypertension are at high risk of complications, particularly cardiovascular events, and optimization of medical treatment remains the cornerstone of their management. Such optimization should be based on simple algorithms and include the use of aldosterone antagonists. The available data from clinical trials do not support the use of device-based approaches such as renal denervation, baroreflex activation therapy or arteriovenous anastomosis for the treatment of resistant hypertension in the majority of patients. Therefore, device treatment remains a last-resort for patients with truly resistant hypertension in the context of clinical research in highly skilled tertiary referral centres. Future research should focus on improving understanding of the intrinsic (physiological and psychological factors) and extrinsic (environmental stressors) mechanisms that contribute to a lack of response to blood-pressure-lowering drugs in adherent patients. The use of biomarkers to identify patients with early target organ damage and new technologies, such as renal nerve stimulation, to predict blood pressure responses to renal denervation could aid the selection of patients who might benefit from device therapies.

PMID:
29700488
DOI:
10.1038/s41581-018-0006-6

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center